Ambrosini V, Marzola MC, Rubello D et al (2010) (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:46–48PubMedCrossRef

Beheshti M, Pöcher S, Vali R et al (2009) The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 19:1425–1434PubMedCrossRef

Beuthien-Baumann B, Strumpf A, Zessin J et al (2007) Diagnostic impact of PET with ¹⁸F-FDG, ¹⁸F-DOPA and 3-O-methyl-6-[¹⁸F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604–1609PubMedCrossRef

Bodei L, Handkiewicz-Junak D, Grana C et al (2004) Receptor radionuclide therapy with ⁹⁰Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65–71PubMedCrossRef

Castellucci P, Pou Ucha J, Fuccio C et al (2011) Incidence of increased ⁶⁸Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52:886–890PubMedCrossRef

Conry BG, Papathanasiou ND, Prakash V et al (2010) Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:49–57PubMedCrossRef

Hoegerle S, Altehoefer C, Ghanem N et al (2001) ¹⁸F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71PubMedCrossRef